Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 14Head & Neck 11Genitourinary 7Gastrointestinal 5Endocrine 5Breast 4Sarcoma 3Gynecologic 3CNS 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1

Conditions

Gliosarcoma 2Glioblastoma 2Oligodendroglioma 1Glioma 1Disease Progression 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 23Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × vandetanib × CNS × Clear all
NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed
119 enrolled 15 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00995007 2016-03-29

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
112 enrolled 12 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡